Vectura develops inhaled therapies principally for the treatment of respiratory diseases. Inhaled formulation development is increasingly complex with a wide variety of small molecules and biologics, increasing use of combination products and the need for targeted lung delivery or deep lung deposition
for systemic delivery. We offer formulation services for DPI, pMDI and nebuliser development,
including small molecules and biologics, complex combinations and generic products.
Registrars:
Key Personnel
Non-Executive Chairman:
Bruno Angelici
Senior Independent Non-Executive Director:
Jeanne Thoma
Independent Non-Executive Director:
Juliet Thompson, Jeanne Hecht, Kevin Matthews, Per-Olof Andersson
CEO and Executive director:
Will Downie
CFO & Executive Director:
Paul Fry
Contact Details
Address:
One Prospect West, Chippenham, Wiltshire, United Kingdom